# Tuvalu Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Tuvalu HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Tuvalu (TUV)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $889.4K
- Products: 31
- Buyer markets: 7
- Average CAGR: +3.9%
- Global sector size: $15.7B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $13.6B | $3.8K | $5.2B | +13.2% | 1 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $1.6B | $594.9 | $1.0B | +34.6% | 1 | +0.0% |
| HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $375.3M | $373.8K | $125.6M | +126.7% | 1 | +0.2% |
| HS 382491 - Chemical products, mixtures and preparations: consisting mainly of (5-ethyl-2-methyl-2-oxido-1,3,2-dioxaphosphinan-5-yl)methyl methyl methylphosphonate and bis[(5-ethyl-2-methyl-2-oxido-1,3,2-dioxaphosphinan-5-yl)methyl] methylphosphonate | $46.5M | $594.9 | $77.0M | +34.6% | 1 | +0.0% |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $23.6M | $315.1 | $9.9M | -25.4% | 2 | +0.0% |
| HS 293980 - Alkaloids: natural or reproduced by synthesis, and their salts, esters and other derivatives n.e.c. in heading no. 2939 | $3.5M | $373.8K | $3.2M | +126.7% | 1 | +16.1% |
| HS 300220 - Vaccines: for human medicine | $5.2M | $12.7 | $2.8M | +4.8% | 1 | +0.0% |
| HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $3.0M | $20.6 | $2.0M | +8.9% | 1 | +0.0% |
| HS 382484 - Chemical products, mixtures and preparations: containing aldrin, camphechlor (toxaphene), chlordane, chlordecone, DDT (chlorfenotane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane), dieldrin, endosulfan, endrin, heptachlor or mirex | $1.6M | $594.9 | $1.6M | +34.6% | 1 | +0.0% |
| HS 382488 - Chemical products, mixtures and preparations: containing goods specified in Subheading Note 3 to this Chapter: containing tetra-, penta-, hexa-, hepta- or octabromodiphenyl ethers | $1.4M | $594.9 | $1.3M | +34.6% | 1 | +0.1% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $1.6M | $9.3 | $1.1M | -25.0% | 1 | +0.0% |
| HS 300450 - Medicaments: containing vitamins or their derivatives, for therapeutic or prophylactic use, packaged for retail sale | $1.1M | $4.3 | $921.0K | -33.9% | 1 | +0.0% |
| HS 300590 - Wadding, gauze, bandages and similar articles: (excluding adhesive dressings), impregnated or coated with pharmaceutical substances, packaged for retail sale | $1.3M | $5.4 | $878.4K | -21.5% | 1 | +0.0% |
| HS 300410 - Medicaments: containing penicillins, streptomycins or their derivatives, for therapeutic or prophylactic uses, packaged for retail sale | $1.2M | $10.8 | $671.1K | -32.9% | 1 | +0.0% |
| HS 292690 - Nitrile-function compounds: n.e.s. in heading no. 2926 | $2.1M | $81.5K | $622.1K | -25.9% | 1 | +2.5% |
| HS 320890 - Paints and varnishes: based on polymers n.e.s. in heading no. 3208, dispersed or dissolved in a non-aqueous medium | $1.2M | $23.5 | $527.3K | +3.5% | 1 | +0.0% |
| HS 300320 - Medicaments: containing antibiotics other than penicillins, streptomycins and their derivatives, for therapeutic or prophylactic uses, (not in measured doses, not packaged for retail sale) | $692.2K | $29.6 | $358.8K | +0.8% | 1 | +1.0% |
| HS 300510 - Dressings, adhesive: and other articles having an adhesive layer, packed for retail sale for medical, surgical, dental or veterinary purposes | $571.3K | $7.5 | $344.2K | -10.6% | 1 | +0.0% |
| HS 300290 - Toxins, cultures of micro-organisms (excluding yeasts) and similar products | $321.3K | $1.3 | $333.4K | +2.5% | 1 | +0.0% |
| HS 330610 - Oral or dental hygiene preparations: dentifrices | $524.1K | $46.9K | $275.8K | +8.4% | 1 | +14.6% |
| HS 381900 - Hydraulic fluids: for brakes and other prepared liquids for hydraulic transmission, not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $492.9K | $6.1K | $240.8K | +56.8% | 1 | +1.0% |
| HS 382487 - Chemical products, mixtures and preparations: containing goods specified in Subheading Note 3 to this Chapter: containing perfluorooctane sulphonic acid, its salts, perfluorooctane sulphonamides, or perfluorooctane sulphonyl fluoride | $192.1K | $594.9 | $213.2K | +34.6% | 1 | +1.8% |
| HS 382478 - Mixtures containing halogenated derivatives of methane, ethane or propane: containing perfluorocarbons (PFCs) or hydrofluorocarbons (HFCs), but not containing chlorofluorocarbons (CFCs) or hydrochlorofluorocarbons (HCFCs) | $261.9K | $1.2 | $209.8K | +5.3% | 1 | +0.0% |
| HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $536.8K | $4.9 | $209.4K | -48.3% | 1 | +0.0% |
| HS 300660 - Pharmaceutical goods: chemical contraceptive preparations based on hormones or spermicides | $328.1K | $1.5 | $164.7K | -30.5% | 1 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $190.7K | $1.8 | $140.5K | -22.3% | 1 | +0.0% |
| HS 300610 - Pharmaceutical goods: sterile surgical catgut, suture materials, tissue adhesives, laminaria, laminaria tents, absorbable surgical or dental haemostatics, and surgical or dental adhesion barriers | $152.7K | $4.3 | $119.6K | -32.4% | 1 | +0.0% |
| HS 300630 - Pharmaceutical goods: opacifying preparations for x-ray examinations, diagnostic reagents designed to be administered to the patient | $163.9K | $2.6 | $105.9K | -18.3% | 1 | +0.0% |
| HS 283620 - Carbonates: disodium carbonate | $84.2K | $13.0 | $74.5K | +1.1% | 1 | +0.0% |
| HS 300432 - Medicaments: containing corticosteroid hormones, their derivatives or structural analogues (but not containing antibiotics), for therapeutic or prophylactic uses, packaged for retail sale | $98.9K | $1.6 | $70.2K | -61.2% | 1 | +0.0% |
| HS 382590 - Residual products of the chemical or allied industries, not elsewhere specified or included: n.e.c. in 3825 or 27.10 | $50.5K | $0.4 | $41.8K | +5.4% | 1 | +0.0% |

## Best markets

- Netherlands (NLD): $5.2B calculated opportunity across 1 products.
- France (FRA): $1.1B calculated opportunity across 5 products.
- United Kingdom (GBR): $128.8M calculated opportunity across 2 products.
- Fiji (FJI): $19.8M calculated opportunity across 20 products.
- Saint Kitts and Nevis (KNA): $1.5M calculated opportunity across 2 products.
- Slovenia (SVN): $622.1K calculated opportunity across 1 products.
- Papua New Guinea (PNG): $275.8K calculated opportunity across 1 products.

## Growth stars

- HS 293359: +126.7% average CAGR, $125.6M calculated opportunity.
- HS 293980: +126.7% average CAGR, $3.2M calculated opportunity.
- HS 381900: +56.8% average CAGR, $240.8K calculated opportunity.
- HS 382499: +34.6% average CAGR, $1.0B calculated opportunity.
- HS 382491: +34.6% average CAGR, $77.0M calculated opportunity.
- HS 382484: +34.6% average CAGR, $1.6M calculated opportunity.
- HS 382488: +34.6% average CAGR, $1.3M calculated opportunity.
- HS 382487: +34.6% average CAGR, $213.2K calculated opportunity.
- HS 300215: +13.2% average CAGR, $5.2B calculated opportunity.
- HS 300390: +8.9% average CAGR, $2.0M calculated opportunity.

## Diversification opportunities

- HS 300490: 2 buyer markets, $9.9M calculated opportunity.
- HS 300215: 1 buyer markets, $5.2B calculated opportunity.
- HS 382499: 1 buyer markets, $1.0B calculated opportunity.
- HS 293359: 1 buyer markets, $125.6M calculated opportunity.
- HS 382491: 1 buyer markets, $77.0M calculated opportunity.
- HS 293980: 1 buyer markets, $3.2M calculated opportunity.
- HS 300220: 1 buyer markets, $2.8M calculated opportunity.
- HS 300390: 1 buyer markets, $2.0M calculated opportunity.
- HS 382484: 1 buyer markets, $1.6M calculated opportunity.
- HS 382488: 1 buyer markets, $1.3M calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.